HEC ChangJiang Pharmaceutical's production projects for the raw materials of Glargine and Insulin Aspart are about to start. Insulin preparations related to this raw material are expected to go on the market after obtaining certification next year. Recently, the reporter came to the factory to visit the construction of the Glargine and Insulin Aspart API projects, and learned that the project can achieve an annual output of 200kg insulin glargine and 450kg insulin aspart.
In June this year, HEC ChangJiang Pharmaceutical's recombinant human insulin injection was approved by the State Food and Drug Administration. This is the first insulin product approved for marketing by the manufacture. The upcoming production of glargine, insulin aspart bulk drugs belonging to the latest third-generation insulin products. With the implementation of the insulin project, HEC ChangJiang Pharmaceutical will have an annual production capacity of more than 1 ton of insulin raw materials and 160 million preparations.
Recombinant human insulin injection is not only the first insulin product approved by HEC ChangJiang Pharmaceutical, but also the first approved biological product in the history of Yichang Pharmaceutical. It represents that the Yichang pharmaceutical industry has truly moved towards the high end of the industrial chain. In the field of diabetes, HEC ChangJiang Pharmaceutical has made a full product layout and will become one of the 10 full-series insulin manufacturers in the world.